US 11,897,875 B2
Deuterated Alpha5 subunit-selective negative allosteric modulators of gamma-aminobutyric acid type a receptors as fast acting treatment for depression and mood disorders
Scott Thompson, Baltimore, MD (US); Adam Van Dyke, Baltimore, MD (US); Craig Thomas, Gaithersburg, MD (US); and Patrick Morris, Laurel, MD (US)
Assigned to UNIVERSITY OF MARYLAND, BALTIMORE, Baltimore, MD (US); and THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, Bethesda, MD (US)
Filed by UNIVERSITY OF MARYLAND, BALTIMORE, Baltimore, MD (US); and THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, Bethesda, MD (US)
Filed on Aug. 9, 2022, as Appl. No. 17/883,734.
Application 17/883,734 is a division of application No. 16/642,445, granted, now 11,459,320, previously published as PCT/US2018/048339, filed on Aug. 28, 2018.
Claims priority of provisional application 62/550,826, filed on Aug. 28, 2017.
Prior Publication US 2022/0396572 A1, Dec. 15, 2022
Int. Cl. C07D 417/14 (2006.01); A61P 25/24 (2006.01); C07D 261/08 (2006.01); C07D 413/12 (2006.01); C07D 413/14 (2006.01); A61K 9/19 (2006.01); A61K 45/06 (2006.01)
CPC C07D 417/14 (2013.01) [A61P 25/24 (2018.01); C07D 261/08 (2013.01); C07D 413/12 (2013.01); C07D 413/14 (2013.01); A61K 9/19 (2013.01); A61K 45/06 (2013.01); C07B 2200/05 (2013.01)] 10 Claims
 
1. A method of treating a depression-related disorder in a human subject in need thereof, comprising administering a therapeutically effective amount of the deuterated GABAA5-NAM compound of Formula Ito the subject:

OG Complex Work Unit Chemistry
wherein R1, R2, and R3 each independently are H or D, with the proviso that at least one of R1, R2 and R3 is D, and wherein R4 and R5 each independently are H or D.